Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Ani Pharmaceuticals (ANIP) over the last 16 years, with Sep 2025 value amounting to $6.1 million.

  • Ani Pharmaceuticals' Capital Expenditures rose 26.83% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year decrease of 7.05%. This contributed to the annual value of $16.2 million for FY2024, which is 83.09% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Capital Expenditures is $6.1 million, which was up 52.04% from $4.0 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Capital Expenditures peaked at $6.1 million during Q3 2025, and registered a low of $356,000 during Q4 2021.
  • Moreover, its 3-year median value for Capital Expenditures was $2.5 million (2023), whereas its average is $3.4 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 83.13% in 2021, then surged by 781.46% in 2022.
  • Ani Pharmaceuticals' Capital Expenditures (Quarterly) stood at $356,000 in 2021, then spiked by 781.46% to $3.1 million in 2022, then fell by 27.37% to $2.3 million in 2023, then rose by 5.05% to $2.4 million in 2024, then rose by 26.83% to $6.1 million in 2025.
  • Its Capital Expenditures stands at $6.1 million for Q3 2025, versus $4.0 million for Q2 2025 and $2.5 million for Q1 2025.